Analyst Price Targets — XERS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 9:28 pm | — | Barclays | $9.00 | $6.99 | TheFly | Xeris Biopharma initiated with an Overweight at Barclays |
| October 29, 2025 12:14 pm | Leland Gershell | Oppenheimer | $18.00 | $9.97 | TheFly | Xeris Biopharma price target raised to $18 from $8 at Oppenheimer |
| March 7, 2025 12:02 pm | — | Piper Sandler | $4.00 | $4.24 | TheFly | Xeris Biopharma price target raised to $4 from $3 at Piper Sandler |
| November 11, 2024 12:23 pm | Oren Livnat | H.C. Wainwright | $6.60 | $3.25 | StreetInsider | Xeris Pharmaceuticals (XERS) PT Raised to $6.60 at H.C. Wainwright |
| October 23, 2024 6:18 am | Leland Gershell | Oppenheimer | $5.00 | $3.02 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS) |
| May 10, 2024 8:29 am | David Amsellem | Piper Sandler | $3.00 | $1.85 | StreetInsider | Xeris Pharmaceuticals (XERS) PT Lowered to $3 at Piper Sandler |
| April 28, 2022 9:49 am | — | Craig-Hallum | $6.50 | $2.33 | Benzinga | Craig-Hallum Initiates Coverage On Xeris Biopharma Holdings with Buy Rating, Announces Price Target of $6.5 |
Latest News for XERS
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. Th
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The corrected release reads: XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient…
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its…
CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XERS.
U.S. House Trading
No House trades found for XERS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.